Nick Van Den Broeck

• Contributed significantly to the implementation and validation of new instrumentation and methods to expand internal sample processing and analysis capacities
• Took ownership in the design, optimization and evaluation of various laboratory procedures in the context of ambulatory and in-human challenge clinical trials in adherence to ISO9001 and latest GCP/GCLP guidelines
• Actively provided input in the validation of biosafety infrastructure

Contributed to the discovery and target deconvolution of Coronavirus antivirals by:

• Developing and execution of in vitro assays, including RT-qPCR, RT-dPCR, and High-Content Imaging (HCI) based methods enabling high throughput assessment of lead compounds for their antiviral effects
• Expansion of molecular cloning capabilities

Striving for operational excellence:

• Taking the lead in design, move and optimization of BSL-3 infrastructure
• Serve as operational lead of the CD-Corona discovery team, by efficient management and allocation of resources
• Pro-active communication of infrastructure/operational factors impacting lab activity
• Contribution to several scientific publications in high-impact journals
• Fulfilled an active role in various scientific and technical core teams, connecting colleagues cross- and intra-site

Development, optimization, and validation of antiviral assays within the
Coronavirus discovery team using a broad portfolio of technologies, including:

• High-throughput cell-based methods encompassing fluorescence and
  luminescence read-outs
• Molecular biology techniques encompassing RT-qPCR and NGS workflows

Assisted in development and optimisation of multiplex PCR-based target enrichment assays in ISO13485 environment.

• Supported validation and quality control of assays utilising Illumina NGS, capillary electrophoresis, and various library preparation methods.
• Aided in automation of library preparation methods on Agilent Bravo NGS option A.
• Contributed to project management activities using Project Insight (PI) tool for estimation of project timelines and resource allocation.

Manufacturing and Quality Control of Multiplicom CE-IVD and RUO products under ISO13485 regulations following tight production timeslots:

• Meticulous adherence to GDP/GLP/GMP guidelines
• Monitoring and documentation of deviations
• Initiating CAPA and Continuous Improvement (CI) projects

Evaluation and quantification of impact on the prevalence of bovine cysticercosis by postmortem detection techniques

• Detection of Taenia species by antigen ELISA
• Molecular characterization of lesions by PCR-RFLP
• Analysis of South-East Asia/Central-Africa Field collected Mosquitoes by means of molecular tools
• Performed Sample treatment and extraction of viral RNA in BSL-3 environment
• Detection of Plasmodium spp. using antigen ELISA and (q-)PCR
• Molecular fingerprinting of arthropod vectors
• Quality assurance responsible
• Maintained lab equipment to ensure accurate test results.